Ally Bridge Group (NY) LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Ally Bridge Group (NY) LLC reported 23 stock positions worth $77.6 million. Its top holding was Minerva Neurosciences (NERV) at 15.6% of the portfolio, followed by Promis Neurosciences (PMN, 10.5%) and First Tracks Biotherapeutics (TRAX, 7.4%). Compared with Q1 2026, it opened 10 new positions, sold out of 8, added to 2 and reduced 9. The biggest buy was a new position in First Tracks Biotherapeutics (TRAX) and the biggest sale an exit from Praxis Precision Medicines I (PRAX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001822947
- Portfolio Value
- $77.6M (Q2 2026)
- SEC Filing
- 0001193125-26-352338 ↗ filed Aug 14, 2026
Holdings Value
Holdings 23 stocks · $77.6M
| NERV Minerva Neurosciences Inc. | 15.56% | 2,175,802 | $12.1M | Add +31.4% |
| PMN Promis Neurosciences Inc. | 10.52% | 620,319 | $8.2M | Add +49.8% |
| TRAX First Tracks Biotherapeutics | 7.37% | 284,287 | $5.7M | New |
| AXSM Axsome Therapeutics Inc. | 5.20% | 16,493 | $4.0M | New |
| ASMB Assembly Biosciences Inc. | 4.96% | 140,000 | $3.8M | New |
| WHWK Whitehawk Therapeutics Inc. | 4.83% | 817,939 | $3.7M | No change |
| EWTX Edgewise Therapeutics Inc. | 4.36% | 83,300 | $3.4M | Reduce -48.3% |
| CLYM Climb Bio Inc. | 4.19% | 249,172 | $3.2M | New |
| KURA Kura Oncology Inc. | 4.10% | 290,000 | $3.2M | New |
| CTMX Cytomx Therapeutics Inc. | 3.75% | 775,000 | $2.9M | Reduce -13.9% |
| AVTX Avalo Therapeutics Inc. | 3.57% | 150,000 | $2.8M | New |
| PALI Palisade Bio Inc. | 3.31% | 1,229,000 | $2.6M | New |
| SLDB Solid Biosciences Inc. | 3.30% | 255,959 | $2.6M | Reduce -66.6% |
| ANTX AN2 Therapeutics Inc. | 3.28% | 526,315 | $2.5M | No change |
| URGN Urogen Pharma Ltd. | 3.28% | 69,183 | $2.5M | Reduce -65.8% |
| CATX Perspective Therapeutics Inc. | 3.27% | 743,958 | $2.5M | Reduce -19.7% |
| IDYA Ideaya Biosciences Inc. | 3.24% | 67,500 | $2.5M | New |
| IVA Inventiva SA - ADR | 3.09% | 634,800 | $2.4M | Reduce -14.8% |
| ALMS Alumis Inc. | 2.77% | 76,459 | $2.2M | Reduce -54.2% |
| OVID Ovid Therapeutics Inc. | 2.17% | 624,561 | $1.7M | Reduce -77.8% |
| EPRX Eupraxia Pharmaceuticals Inc. | 2.15% | 252,175 | $1.7M | Reduce -61.8% |
| IBIO Ibio Inc. | 0.88% | 390,147 | $683K | New |
| TRAW Traws Pharma Inc. | 0.85% | 786,236 | $663K | New |
Options reported separately and not counted above: DFTX calls ($18.8M), ABVX calls ($16.7M).
Portfolio Sells Q1 2026 → Q2 2026
| PRAX Praxis Precision Medicines I | Sold out | 0.00% | −10.50 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −6.65 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −5.74 |
| TARS Tarsus Pharmaceuticals Inc. | Sold out | 0.00% | −5.64 |
| OVID Ovid Therapeutics Inc. | Reduce -77.8% | 2.17% | −4.05 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −3.73 |
| CAPR Capricor Therapeutics Inc. | Sold out | 0.00% | −3.44 |
| EPRX Eupraxia Pharmaceuticals Inc. | Reduce -61.8% | 2.15% | −2.60 |
| IKT Inhibikase Therapeutics Inc. | Sold out | 0.00% | −2.21 |
| SLDB Solid Biosciences Inc. | Reduce -66.6% | 3.30% | −2.19 |
| RLMD Relmada Therapeutics Inc. | Sold out | 0.00% | −1.46 |
| IVA Inventiva SA - ADR | Reduce -14.8% | 3.09% | −1.02 |
| ALMS Alumis Inc. | Reduce -54.2% | 2.77% | −0.88 |
| EWTX Edgewise Therapeutics Inc. | Reduce -48.3% | 4.36% | −0.68 |
| CATX Perspective Therapeutics Inc. | Reduce -19.7% | 3.27% | −0.57 |
| CTMX Cytomx Therapeutics Inc. | Reduce -13.9% | 3.75% | −0.46 |
| URGN Urogen Pharma Ltd. | Reduce -65.8% | 3.28% | −0.33 |
Portfolio Buys Q1 2026 → Q2 2026
| TRAX First Tracks Biotherapeutics | New | 7.37% | +7.37 |
| NERV Minerva Neurosciences Inc. | Add +31.4% | 15.56% | +5.65 |
| PMN Promis Neurosciences Inc. | Add +49.8% | 10.52% | +5.29 |
| AXSM Axsome Therapeutics Inc. | New | 5.20% | +5.20 |
| ASMB Assembly Biosciences Inc. | New | 4.96% | +4.96 |
| CLYM Climb Bio Inc. | New | 4.19% | +4.19 |
| KURA Kura Oncology Inc. | New | 4.10% | +4.10 |
| AVTX Avalo Therapeutics Inc. | New | 3.57% | +3.57 |
| PALI Palisade Bio Inc. | New | 3.31% | +3.31 |
| IDYA Ideaya Biosciences Inc. | New | 3.24% | +3.24 |
| IBIO Ibio Inc. | New | 0.88% | +0.88 |
| TRAW Traws Pharma Inc. | New | 0.85% | +0.85 |
Options Activity Q1 2026 → Q2 2026
| DFTX Definium Therapeutics Inc. | call | New | 400,000 | $18.8M |
| ABVX Abivax SA-ADR | call | New | 125,000 | $16.7M |
| SLNO Soleno Therapeutics Inc. | put | Sold out | 200,000 | $6.7Mbefore exit |
| CMPX Compass Therapeutics Inc. | call | Sold out | 1,000,000 | $5.3Mbefore exit |
| QURE Uniqure NV | call | Sold out | 300,000 | $4.9Mbefore exit |
| MAZE Maze Therapeutics Inc. | call | Sold out | 100,000 | $3.0Mbefore exit |
| REPL Replimune Group Inc. | call | Sold out | 246,900 | $1.9Mbefore exit |
| KPTI Karyopharm Therapeutics Inc. | call | Sold out | 250,000 | $1.4Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $77.6M | NERV, PMN, TRAX, AXSM, ASMB |
| Q1 2026 | 21 | $100.7M | PRAX, NERV, SLNO, OVID, CMPS |
| Q4 2025 | 13 | $63.0M | ABVX, SLNO, ATAIBECKLEY INC, IVA, NERV |
| Q3 2025 | 18 | $119.4M | SLNO, MDGL, ATAIBECKLEY INC, ASND, LENZ |
| Q2 2025 | 24 | $120.2M | VRNA, SLNO, LENZ, MRUS, ULTRAGENYX PHARMACEUTICAL IN |
| Q1 2025 | 28 | $110.9M | SWTX, VRNA, SLNO, AXSM, TARS |
| Q4 2024 | 30 | $116.6M | ITCI, TARS, INSM, AXSM, XENE |
| Q3 2024 | 29 | $186.8M | INSM, TARS, MRUS, CGON, BPMC |
| Q2 2024 | 25 | $167.9M | SLNO, SRPT, GERN, MRUS, INSM |
| Q1 2024 | 22 | $179.9M | BPMC, SLNO, CGON, XENE, VRNA |